ES2875336T3 - Compuestos aromáticos sustituidos y composiciones farmacéuticas para la prevención y tratamiento de la diabetes - Google Patents

Compuestos aromáticos sustituidos y composiciones farmacéuticas para la prevención y tratamiento de la diabetes Download PDF

Info

Publication number
ES2875336T3
ES2875336T3 ES15849445T ES15849445T ES2875336T3 ES 2875336 T3 ES2875336 T3 ES 2875336T3 ES 15849445 T ES15849445 T ES 15849445T ES 15849445 T ES15849445 T ES 15849445T ES 2875336 T3 ES2875336 T3 ES 2875336T3
Authority
ES
Spain
Prior art keywords
diabetes
compound
alkyl
alkenyl
insulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15849445T
Other languages
English (en)
Spanish (es)
Inventor
Lyne Gagnon
Brigitte Grouix
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Liminal Biosciences Ltd
Original Assignee
Liminal Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liminal Biosciences Ltd filed Critical Liminal Biosciences Ltd
Application granted granted Critical
Publication of ES2875336T3 publication Critical patent/ES2875336T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • C07C57/32—Phenylacetic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/58—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/52—Unsaturated compounds containing hydroxy or O-metal groups a hydroxy or O-metal group being bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES15849445T 2014-10-10 2015-10-08 Compuestos aromáticos sustituidos y composiciones farmacéuticas para la prevención y tratamiento de la diabetes Active ES2875336T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462062526P 2014-10-10 2014-10-10
PCT/CA2015/000531 WO2016054726A1 (en) 2014-10-10 2015-10-08 Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of diabetes

Publications (1)

Publication Number Publication Date
ES2875336T3 true ES2875336T3 (es) 2021-11-10

Family

ID=55652427

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15849445T Active ES2875336T3 (es) 2014-10-10 2015-10-08 Compuestos aromáticos sustituidos y composiciones farmacéuticas para la prevención y tratamiento de la diabetes

Country Status (21)

Country Link
US (1) US10105331B2 (enExample)
EP (1) EP3203998B1 (enExample)
JP (1) JP6676629B2 (enExample)
KR (1) KR20170066614A (enExample)
CN (1) CN106999458B (enExample)
AR (1) AR102248A1 (enExample)
AU (1) AU2015330643B2 (enExample)
BR (1) BR112017007420A2 (enExample)
CA (1) CA2963276A1 (enExample)
DK (1) DK3203998T3 (enExample)
ES (1) ES2875336T3 (enExample)
IL (1) IL251392B (enExample)
MX (1) MX376872B (enExample)
PH (1) PH12017500662B1 (enExample)
PL (1) PL3203998T3 (enExample)
PT (1) PT3203998T (enExample)
RU (1) RU2723486C2 (enExample)
SG (1) SG11201702812PA (enExample)
TW (1) TWI699201B (enExample)
UY (1) UY36354A (enExample)
WO (1) WO2016054726A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201702812PA (en) * 2014-10-10 2017-05-30 Prometic Pharma Smt Ltd Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of diabetes
US10391073B2 (en) * 2014-11-12 2019-08-27 Prometic Pharma Smt Limited Substituted aromatic compounds and pharmaceutical compositions for tissue self-repair and regeneration
CA3112073A1 (en) 2018-10-11 2020-04-16 Basf As Aromatic compounds and pharmaceutical uses thereof
US20240043372A1 (en) * 2020-10-06 2024-02-08 Pharmaceutique Ingenew Inc. Substituted aromatic compounds and pharmaceutical compositions thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635532A (en) * 1991-10-21 1997-06-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia
RU2005128501A (ru) * 2003-02-13 2006-04-27 Веллстат Терапьютикс Корпорейшн (Us) Соединение для лечения метаболических расстройств
CA2580370A1 (en) * 2004-09-15 2006-03-23 Gokhan S. Hotamisligil Reducing er stress in the treatment of obesity and diabetes
AT509045B1 (de) * 2010-01-29 2011-06-15 Planta Naturstoffe Vertriebsges M B H Verbindungen zur behandlung von asthma bronchiale
JP2012072136A (ja) * 2010-09-03 2012-04-12 Erina Co Inc 細胞内代謝促進用組成物、その組成物を含有する糖代謝又は脂質代謝疾患の予防及び／又は治療用医薬製剤、機能性食品及び健康食品
CA2816094A1 (en) * 2010-10-27 2012-07-26 Prometic Biosciences Inc. Compounds and pharmaceutical compositions for uses in diabetes
TWI689490B (zh) * 2013-03-15 2020-04-01 英商邊緣生物科技有限公司 用於治療纖維化之經取代之芳族化合物及相關方法
SG11201702812PA (en) * 2014-10-10 2017-05-30 Prometic Pharma Smt Ltd Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of diabetes

Also Published As

Publication number Publication date
RU2017116106A3 (enExample) 2019-02-13
WO2016054726A1 (en) 2016-04-14
EP3203998A4 (en) 2018-06-20
CN106999458B (zh) 2021-04-13
EP3203998B1 (en) 2021-03-10
SG11201702812PA (en) 2017-05-30
KR20170066614A (ko) 2017-06-14
US10105331B2 (en) 2018-10-23
IL251392A0 (en) 2017-05-29
AR102248A1 (es) 2017-02-15
EP3203998A1 (en) 2017-08-16
MX376872B (es) 2025-03-07
RU2017116106A (ru) 2018-11-12
TW201618763A (zh) 2016-06-01
PL3203998T3 (pl) 2021-09-27
MX2017004738A (es) 2017-08-10
AU2015330643A1 (en) 2017-05-04
UY36354A (es) 2016-06-01
PT3203998T (pt) 2021-06-07
PH12017500662B1 (en) 2022-08-19
RU2723486C2 (ru) 2020-06-11
IL251392B (en) 2020-11-30
CN106999458A (zh) 2017-08-01
JP6676629B2 (ja) 2020-04-08
PH12017500662A1 (en) 2017-10-02
AU2015330643B2 (en) 2020-05-14
TWI699201B (zh) 2020-07-21
US20170209399A1 (en) 2017-07-27
JP2017530182A (ja) 2017-10-12
BR112017007420A2 (pt) 2018-01-16
DK3203998T3 (da) 2021-05-31
CA2963276A1 (en) 2016-04-14

Similar Documents

Publication Publication Date Title
AU2011356584B2 (en) Compounds and pharmaceutical compositions for uses in diabetes
EP2275108B1 (en) Pharmaceutical preparation comprising dpp-iv inhibitor and other diabetes therapeutic agent in concomitant or combined form
US20120040898A1 (en) Pharmaceutical compositions
ES2875336T3 (es) Compuestos aromáticos sustituidos y composiciones farmacéuticas para la prevención y tratamiento de la diabetes
WO2012090225A2 (en) Novel cocrystals / molecular salts of metformin with oleoylethanolamide as an effective anti-diabetic + anti- obesity agent
EP2945618B1 (en) Combinations of a glp1r agonist and metformin and use thereof for the treatment of type 2 diabetes and other disorders
Kshirsagar et al. DPP IV inhibitors: successes, failures and future prospects
JP2018090589A (ja) 肝機能改善法
EP2139320A1 (en) Methods and compositions of derivatives of probucol for the treatment of diabetes
CA2598491A1 (en) Diastereoisomers of 4-hydroxyisoleucine and uses thereof
HK1236421B (en) Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of diabetes
WO2011002011A1 (ja) Sglt1阻害薬とdpp-iv阻害薬を組み合わせてなる医薬
WO2012101292A1 (es) Derivados de 1,2,4-oxadiazol como fármacos moduladores del receptor para el péptido glp-1
Prabavathy et al. Linagliptin-a novel DPP-IV inhibitor
WO2015134357A1 (en) Modulators of insulin receptor
AU2016202866A1 (en) Pharmaceutical compositions
AU2014221222A1 (en) Pharmaceutical compositions